bioMerieux (OTCMKTS:BMXMF) & XWELL (NASDAQ:XWEL) Head to Head Contrast

bioMerieux (OTCMKTS:BMXMF) and XWELL (NASDAQ:XWEL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Insider and Institutional Ownership

8.7% of XWELL shares are owned by institutional investors. 13.9% of XWELL shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares bioMerieux and XWELL”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioMerieux	$4.31 billion	3.54	$467.68 million	N/A	N/A
XWELL	$30.60 million	0.16	-$16.85 million	($4.10)	-0.21

bioMerieux has higher revenue and earnings than XWELL.

Profitability

This table compares bioMerieux and XWELL’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioMerieux	N/A	N/A	N/A
XWELL	-63.18%	-265.41%	-72.67%

Analyst Ratings

This is a summary of current recommendations and price targets for bioMerieux and XWELL, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioMerieux	0	1	0	0	2.00
XWELL	1	0	0	0	1.00

Volatility & Risk

bioMerieux has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, XWELL has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.

Summary

bioMerieux beats XWELL on 7 of the 10 factors compared between the two stocks.

About bioMerieux

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

About XWELL

XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.